30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
At long last, the Setting Every Community Up for Retirement Enhancement Act of 2019 (the SECURE Act)...
Read More >
On January 28, 2020, the Federal Trade Commission announced revised notification thresholds pursuant...
Read More >
If your business is one of the 570,000 issued a No-Match Letter from the Social Security Administrat...
Read More >
Hard on the heels of the muckle of anti-trust filings against the huge U.S. technology companies in ...
Read More >
In April 2019, the Department of Health and Human Services (HHS) released guidance indicating that a...
Read More >
On October 8, 2019, the Governor of Puerto Rico signed into law Act No. 150 of October 8, 2019 (“Ac...
Read More >